Organ-specific effects of dark treatment on photosynthesis and the expression of photosynthesis-related genes

2011 ◽  
Vol 55 (2) ◽  
pp. 269-278 ◽  
Author(s):  
K. Mishev ◽  
E. D. Ananiev ◽  
K. Humbeck
2012 ◽  
Vol 11 (2) ◽  
pp. 161-172 ◽  
Author(s):  
Seyhan Sahan-Firat ◽  
Necmiye Canacankatan ◽  
Belma Korkmaz ◽  
Hatice Yildirim ◽  
Lulufer Tamer ◽  
...  

2020 ◽  
Vol 229 ◽  
pp. 105677
Author(s):  
Elvira Mennillo ◽  
Carlo Pretti ◽  
Francesca Cappelli ◽  
Giacomo Luci ◽  
Luigi Intorre ◽  
...  

2011 ◽  
Vol 33 (6) ◽  
pp. 2239-2247 ◽  
Author(s):  
Iva McCarthy-Suárez ◽  
Manuel Gómez ◽  
Luis A. del Río ◽  
José M. Palma

2004 ◽  
Vol 10 (8) ◽  
pp. 534-539 ◽  
Author(s):  
Lisbeth A. Welniak ◽  
Lynnette Shorts ◽  
Jeff Subleski ◽  
Bruce R. Blazar ◽  
Robert H. Wiltrout ◽  
...  

2005 ◽  
Vol 73 (3) ◽  
pp. 1466-1474 ◽  
Author(s):  
Jennifer M. Ritchie ◽  
Matthew K. Waldor

ABSTRACT The genes encoding the enterohemorrhagic Escherichia coli (EHEC) type III secretion system (TTSS) and five effector proteins secreted by the TTSS are located on the locus of enterocyte effacement (LEE) pathogenicity island. Deletion of tir, which encodes one of these effector proteins, results in a profound reduction (∼10,000-fold) in EHEC colonization of the infant rabbit intestine, but the in vivo phenotypes of other LEE genes are unknown. Here, we constructed in-frame deletions in escN, the putative ATPase component of the TTSS, and the genes encoding the four other LEE-encoded effector proteins, EspH, Map, EspF, and EspG, to investigate the contributions of the TTSS and the translocated effector proteins to EHEC pathogenicity in infant rabbits. We found that the TTSS is required for EHEC colonization and attaching and effacing (A/E) lesion formation in the rabbit intestine. Deletion of escN reduced EHEC recovery from the rabbit intestine by ∼10,000-fold. Although EspH, Map, EspF, and EspG were not required for A/E lesion formation in the rabbit intestine or in HeLa cells, these effector proteins promote EHEC colonization. Colonization by the espH and espF mutants was reduced throughout the intestine. In contrast, colonization by the map and espG mutants was reduced only in the small intestine, indicating that Map and EspG have organ-specific effects. EspF appears to down-regulate the host response to EHEC, since we observed increased accumulation of polymorphonuclear leukocytes in the colonic mucosa of rabbits infected with the EHEC espF mutant. Thus, all the known LEE-encoded effector proteins influence EHEC pathogenicity.


2007 ◽  
Vol 58 (3) ◽  
pp. 490-496 ◽  
Author(s):  
James P.B. O'Connor ◽  
Alan Jackson ◽  
Giovanni A. Buonaccorsi ◽  
David L. Buckley ◽  
Caleb Roberts ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Elizabeth M. Sajdel-Sulkowska

SARS-CoV-2, primarily considered a respiratory virus, is increasingly recognized as having gastrointestinal aspects based on its presence in the gastrointestinal (GI) tract and feces. SARS-CoV-2 uses as a receptor angiotensin-converting enzyme 2 (ACE-2), a critical member of the renin-angiotensin-aldosterone system (RAAS) involved in the regulation of blood pressure and fluid system. In addition to the systemic endocrine functions, RAAS components are also involved in intracrine and organ-specific local functions. The angiotensin-converting enzyme 2 (ACE-2) is a key component of RAAS and a receptor for SARS-CoV-2. It is expressed in many tissues with gastrointestinal (GI) tract ACE-2 levels far exceeding those in the respiratory tract. SARS-CoV-2 binding to its receptor results in a deficiency of ACE-2 activity in endocrine, intracrine, and local lung and GI tract ACE-2. The local ACE-2 has different organ-specific functions, including hypertension-independent activities; dysregulations of these functions may contribute to multiorgan COVID-19 pathology, its severity, long-term effects, and mortality. We review supporting evidence from this standpoint. Notably, COVID-19 comorbidities involving hypertension, obesity, heart disease, kidney disease, and diabetes are associated with gastrointestinal problems and display ACE-2 deficits. While RAAS inhibitors target both endocrine and intracrine ACE-2 activity, the deficit of the local ACE-2 activity in the lungs and more so in the gut have not been targeted. Consequently, the therapeutic approach to COVID-19 should be carefully reconsidered. Ongoing clinical trials testing oral probiotic bound ACE-2 delivery are promising.


Sign in / Sign up

Export Citation Format

Share Document